Legal Representation
Attorney
Frances M. Jagla
USPTO Deadlines
Next Deadline
327 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2020-09-29)
Due Date
September 29, 2026
Grace Period Ends
March 29, 2027
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
35 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Sep 29, 2025 | REM1 | E | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | Loading... |
| Jun 17, 2024 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Jun 17, 2024 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Jun 17, 2024 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Jun 17, 2024 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Jun 17, 2024 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| May 1, 2024 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Apr 24, 2024 | ASCK | I | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | Loading... |
| Sep 29, 2020 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jul 14, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jul 14, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jun 24, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jun 8, 2020 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jun 8, 2020 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Jun 8, 2020 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jun 8, 2020 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jun 8, 2020 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| May 29, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| May 28, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| May 28, 2020 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
| Dec 4, 2019 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Dec 4, 2019 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Dec 4, 2019 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Dec 2, 2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Dec 1, 2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Dec 1, 2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jun 19, 2019 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jun 19, 2019 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jun 19, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jun 19, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| May 7, 2019 | AMPX | O | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | Loading... |
| May 6, 2019 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Apr 28, 2019 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED | Loading... |
| Apr 25, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Apr 12, 2019 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
pharmaceuticals and pharmaceutical preparations for human and veterinary use for the treatment and prevention of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer, sepsis, and restenosis; vaccine preparations; vaccines; biological preparations in the nature of antibodies for use in the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer, sepsis, and restenosis; antibodies sold as an ingredient of pharmaceuticals for the treatment of treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer, sepsis, and restenosis; diagnostic preparations for medical or veterinary purposes; biological preparations for human medical diagnostics and analysis for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer, sepsis, and restenosis; sanitary preparations for medical use; medical diagnostic reagents; clinical medical reagents; biological preparations for medical and veterinary purposes for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer, sepsis, and restenosis
Class 042
research and development in the pharmaceutical and biotechnology fields; research and development of vaccines and medicines; scientific and technological services and research and design services, namely, scientific research, analysis, and testing services in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; biological research and medical research; chemical and biochemical analysis services; laboratory research in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; clinical research in connection with the treatment and prevention of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer, sepsis, and restenosis; conducting clinical trials for others; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development services in the field of antibodies
Classification
International Classes
005
042